Sugi Predict

Sugi Predict / Compounds / SCHEMBL209164

SCHEMBL209164

SCHEMBL209164

CC(C)(C)OC(=O)N1[C@@H](C=O)COC1(C)C

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SPHK1 Q9NYA1 1/20 0.50
▸ BRD4 O60885 1/20 0.39
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ HCRTR2 O43614 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ DDB1 Q16531 1/20 0.34
▸ CRBN Q96SW2 1/20 0.34
▸ NR1H2 P55055 2/20 0.34
▸ HSD11B2 P80365 1/20 0.33
▸ RECQL P46063 1/20 0.32
▸ CTSK P43235 1/20 0.32
▸ EPHX2 P34913 1/20 0.31
▸ HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL222671 1.00 SPHK1 (0.50) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL222670 1.00 SPHK1 (0.50) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL1840177 0.87 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL1370603 0.87 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL1370602 0.87 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL11959795 0.86 SPHK1 (0.44) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL12507489 0.86 SPHK1 (0.44) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL6444864 0.85 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL13964503 0.85 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3
SCHEMBL2615731 0.85 SPHK1 (0.46) SPHK1BRD4CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof CIT THERAPEUTICS, INC. (US) 2026-04-28 — — US disclosed
CN-121574059-A Method and system for controlling synthesis of 6-hydroxy sphingosine and isomer thereof 重庆智合生物医药有限公司 2026-02-27 — — CN disclosed
WO-2026043875-A1 SYNTHESIS OF OXEPANOPROLINES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2026-02-26 — — WO disclosed
EP-4688789-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 — — EP disclosed
US-20260008758-A1 LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF INSMED INCORPORATED 2026-01-08 — — US disclosed
US-20260008787-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE BLOSSOMHILL THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
EP-4649086-A1 PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION Merck Sharp & Dohme LLC (US) 2025-11-19 — — EP disclosed
US-20250243187-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-07-31 — — US disclosed
US-20250223259-A1 PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION MERCK SHARP & DOHME LLC (US) 2025-07-10 — — US disclosed
WO-2025137639-A1 MIXED SEROTONIN RECEPTOR BINDERS FOR TREATMENT OF PSYCHOTIC DISORDERS DELIX THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-6432980-B1 PREVENTION OF COCCIDIOSIS IN POULTRY MERCK & CO., INC. 2002-08-13 — — US disclosed
WO-2002004420-A1 PIPERIDINE COUMPOUNDS FOR USE AS CCR-3 INHIBITORS NOVARTIS AG (CH) 2002-01-17 — — WO disclosed
CN-1330647-A 4-alkenyl (and alkynyl) oxindoles as inhibitors of cell cycle protein dependent kinases, in particular CDK2 HOFFMANN LA ROCHE (CH) 2002-01-09 — — CN disclosed
EP-1157019-A1 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 F. HOFFMANN-LA ROCHE AG (CH) 2001-11-28 — — EP disclosed
US-6303793-B1 INTERMEDIATES FOR CYCLIN-DEPENDENT KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2001-10-16 — — US disclosed
US-6252086-B1 CYCLIN-DEPENDENT KINASES INHIBITORS; ANTICANCER AGENTS HOFFMANN-LA ROCHE INC. 2001-06-26 — — US disclosed
WO-2001034150-A1 ALIPHATIC AMINE SUBSTITUTED PIPERIDYL DIARYL PYRROLE DERIVATIVES AS ANTIPROTOZOAL AGENTS MERCK & CO., INC. (US) 2001-05-17 — — WO disclosed
US-6130239-A INHIBIT CYCLIN-DEPENDENT KINASES HOFFMANN-LA ROCHE INC. (US) 2000-10-10 — — US disclosed
WO-2000035908-A1 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 — — WO disclosed
EP-0710230-B1 1,5-BENZODIAZEPINE DERIVATIVES USEFUL AS CCK OR GASTRIN ANTAGONISTS GLAXO WELLCOME SPA (IT) 1998-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243187-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 SPHK1 2627/4885BRD4 1775/4885CHRM2 4868/4885
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof SUMO1, SUMO3, PSMB6 SPHK1 4465/4885BRD4 485/4885CHRM2 3237/4885
US-20250223259-A1 PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION ACE2, PRSS2, PRSS1 SPHK1 2793/4885BRD4 912/4885CHRM2 787/4885
US-20260008787-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE KRAS, NRAS, HRAS SPHK1 2398/4885BRD4 776/4885CHRM2 4331/4885
US-20260008758-A1 LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF DPP3, DPP7, DPP9 SPHK1 1223/4885BRD4 3066/4885CHRM2 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.